Everly Bio
Everly Bio is a clinical-stage diagnostics company developing a non-invasive sperm analysis test that combines molecular biology and AI to improve outcome for couples going through IVF
Problem & solution
Male infertility contributes to ~50% of infertility cases, yet current sperm tests primarily assess count, motility, and morphology and often fail to predict IVF outcomes. Everly Bio provides a non-invasive molecular test that analyzes RNA in seminal fluid using AI to assess sperm functional health and predict IVF success, enabling more informed treatment decisions and potentially reducing failed IVF cycles.
Primary customers & users
Our primary customers are IVF clinics and fertility centers, with reproductive endocrinologists and IVF physicians as key decision-makers and users. Initially, testing will be offered through a CLIA-certified laboratory and paid out-of-pocket by patients, with future expansion to employers, payers, and broader fertility screening.
Differentiation
Unlike conventional sperm tests that measure count, motility, and morphology, Everly Bio provides a non-invasive molecular assessment of sperm functional health using RNA and AI. It is designed to predict IVF outcomes rather than simply describe sperm characteristics, enabling more informed treatment decisions.
Current traction
Everly Bio has completed a multi-center clinical study in Israel with ~500 couples and identified a molecular signature associated with IVF outcomes. We are preparing a U.S. clinical study with leading fertility centers, with sites aligned for initiation. We have secured a competitive grant from the Israeli Innovation Authority to advance further product development and commercialization
How Summit participants can help
We would value introductions to IVF clinics and fertility leaders, strategic partners in diagnostics and women’s health, investors focused on healthcare and fertility, and employers or benefits platforms exploring fertility solutions. We would appreciate opportunities to validate our commercialization strategy and partners for our U.S. launch.